Valeant Pharmaceuticals International Inc., Laval, Quebec, said it received approval from the FDA for Onexton gel (clindamycin phosphate and benzoyl peroxide), 1.2 percent/3.75 percent, for the once-daily treatment of comedonal (non-inflammatory) and inflammatory acne in patients 12 and older.